Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II trial of the tolerability and preliminary efficacy of APC 100 for the treatment of hormone-refractory (castrate-resistant) prostate cancer

Next Previous
Trial Profile

Phase I/II trial of the tolerability and preliminary efficacy of APC 100 for the treatment of hormone-refractory (castrate-resistant) prostate cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APC 100 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Adamis Pharmaceuticals Corporation

Most Recent Events

  • 29 Feb 2016 Results (n=20) published in the Investigational New Drugs
  • 15 Jul 2015 Planned End Date changed from 1 Aug 2015 to 1 Aug 2017 as per ClinicalTrials.gov record.
  • 15 Jul 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top